医薬品開発におけるバイオマーカー戦略の現状と展望

DOI Web Site 参考文献32件
  • 上野 貴代
    日本製薬工業協会医薬品評価委員会臨床評価部会 ブリストル・マイヤーズスクイブ株式会社
  • 松島 信子
    日本製薬工業協会医薬品評価委員会臨床評価部会 ヤンセンファーマ株式会社
  • 安藤 裕崇
    日本製薬工業協会医薬品評価委員会臨床評価部会 杏林製薬株式会社
  • 片島 正貴
    日本製薬工業協会医薬品評価委員会臨床評価部会 アステラス製薬株式会社
  • 松野 久美
    日本製薬工業協会医薬品評価委員会臨床評価部会 バイエル薬品株式会社
  • 今井 康彦
    日本製薬工業協会医薬品評価委員会臨床評価部会 ブリストル・マイヤーズスクイブ株式会社

書誌事項

タイトル別名
  • Current Status and Future Prospects of Biomarker Strategy for Drug Development

この論文をさがす

説明

<p>In recent years, large-scale genome analysis technology and information processing technology are rapidly progressing in the medical field, which leads a global-wide transformation of the entire medical care. The advancement of technologies also promotes utilization of clinical biomarkers, which play an important role in precision medicine, and clinical biomarker-based medical innovation is currently taking place in various fields in drug development.</p><p>This article discusses the efficient biomarker strategy to achieve precision medicine, and seeks the solutions of addressed issues. The development process of clinical biomarkers is divided into three phases: Discovery, Translational, and Qualification. Discovery section introduces the latest approaches which led to identification of clinical biomarker candidates through omics, and gap between utilization of clinical biomarker in clinical development and clinical application. Translational section introduces points to consider for analytical methods validation, and statistical points such as clinical sensitivity, specificity, and false discovery rate (FDR), for biomarker selection. This section also refers to the importance of genomic cohort studies, as well as the issues related to genome-wide association analysis. Qualification section discusses approaches to show clinical utility of biomarkers, by introducing enrichment strategies, master protocol strategies, etc. In addition, this section refers to new drug application and accelerated review led by biomarker strategies.</p><p>This article describes the current status and prospect of drug development based on the utilization of clinical biomarkers, which is an issue imposed on stakeholders who promote biomarker strategies, and we expect that it will help realize personalized therapy in the future.</p>

収録刊行物

  • 臨床薬理

    臨床薬理 51 (3), 151-160, 2020-05-31

    一般社団法人 日本臨床薬理学会

参考文献 (32)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ